In 2, muscle glycogen was increased. In this family, only males were afflicted,, and the trait was passed through females, suggesting an X-linked pattern of inheritance. The previously described X-1 inked glycogenosis was associated with phosphorylase kinase deficiency. Since this enzyme is present in this family, a new form of X-linked glycogen storage disease is suggested. The hyperglycemic effect of epinephrine is commonly attributed to increased glucose production. After infusion of physiological amounts of epinephrine in adults, glucose production transiently increases without a change in utilization. In the present studies in children, glucose production and utilization rates were estimated after stimulation of endogenous epinephrine with 2-deoxyglucose (50 mg/kg, i.v. over 30 min). In 4 control children plasma epinephrine increased 13 fold to 1330 f 430 (SE) pg/ml and glucose increased by 39 11 mg/dl during 60 min following 2-deoxyglucose Glucose production, measured by primed constant infusion of 6,6-2~2-glucose, was initially 6.1 f 1.1 mg/kg min and did not change.
DECREASED GLUCOSE UTILIZATION WITHOUT INCREASED PRO-DUCTION FOLLOWING STIMULATION OF EPINEPHRINE
The increase in plasma glucose was accounted for by a decrease in glucose utilization of 2.0 + 0.6 mg/kg min. This was not adirect effect of 2-deoxyglucose, because in 4 epinephrine deficient children plasma epinephrine and glucose did not increase . In another study 6 control and 6 epinephrine deficientchildren were given glucose (500 mg/kg, i.v. in 1 min) which was repeated 2 hrs after 2-deoxyglucose. In the controls the disappearance rate of glucose decreased from 2.7 f 0.4 to 1.4 f O.l%/min after 2-deoxyglucose (p<0.01); in the epinephrine deficient subjects the rate did not change (2.1 f 0.3 %/min). These data indicate that in children the hyperglycemic effect of increased endogenous epinephrine is due to decreased glucose utilization. Twin girls were found at 3 no to have fatty liver, transient erythroblastopenia, hypoglycemia, and cardiomyopathy. One twin died suddenly at 7 no; autopsy showed fatty infiltration of the viscera and tissue carnitine was extremely low. In the surviving twin total carnitine was 8-12 uM in plasma, 160 uM in muscle, and 130 uM in liver, all very low. Carnitine, but not its precursor trimethylsine, was low in urine. Urinary Cg-Clo dicarboxylic acids were increased. A t 14 mo, fasting for 10 hr resulted in lethargy and hypoglycemia. Plasma free fatty acids (FFA) were increased, while short and long chain acyl carnitines (SCA,LCA) were low (see Table) . The RQ(COZ/02) and disappearance rate of an i.v. glucose load (3.8 %/min) were relatively high. Treatment with 1-carnitine, 50 mg/kg d, begun at 15 no increased plasma carnitine to 75-90 uM. Muscle, liver, and cardiac function improved; mental development was normal. At 19 no, fasting for 17 hrs was well tolerated with normalization of metabolism: Therapy ). Glucose-6-phosphate was unaltered but fructose-6-phosphate was lower at 0,6 and 9 hrs in MCS pups. Cerebral pyruvate levels were similar however lactate was lower at 3 and 6 hrs after MCS. The cytoplasmic NAD/NADH ratio was increased after MCS at 3 hrs (1394r104~s1005+146). There were no alterations of fetal or neonatal citrate levels. Malate was lower in MCS pups at 3,6 and 9 hrs while oxaloacetate was increased at 0 hrs. Aspartate levels were elevated following MCS at 3 and 6 hrs while glutamine was decreased at 3,6 and 9 hrs. Fetal levels of phosphocreatine (PC) and ATP were equivalent. However cerebral PC was depressed at 3,6 and 9 hrs, while ATP was lower at 6 and 9 hrs after MCS. The total adenine nucleotide pool, though equivalent at birth, became lower at 3,6 and 9 hrs. The cerebral energy reserve was lower in MCS pups at 3,6,9 and 24 hrs. These data suggest that neonatal canine cerebral energy metabolism has been adversely affected following MCS. Energy production in particular is most affected as ATP, PC and the total adenine nucleotide pool are diminished. Glutamine and glutamate are said to serve to remove excess of NHq in animals. But the detailed relationship in ammonia metabolism between NHq and amino acids was not known in urea cycle enzymopathies. We investigated the ammonia metabolism of a patient with O W deficiency (an 8-year-old female) using 15N tracer method. 1 5~~4~1 was administered orally to the patient (500mg) and a volunteer (19). The l5N excess ratios of amino acids and urea in the serum were examined during time course after the administration of 1 5~~4~1 .
METABOLIC EFFECTS OF TREATMENT OF SYSTEMIC CARNITINE
The 15N excess ratios of amino acids were examined in the form of the N-TFA-0 butylester derivatives using gas chromato-mass spectrometry. Urea 15N was assayed using an isotope ratio mass spectrometry. The incorporation of 15N into urea in the patient was decreased to one forth compared to that in the control. The large amount of 15N was incorporated immediately into alanine, asparagine,, glutamine(d-N) and glutamate. This pattern is very significant compared to the normal control. But the incorporation of 1 5~~4~1 into another amino acids in the patient was the same as that in the control. Accordingly, we suggest that alanine and asparagine could serve to remove excess of (+0.41), of gestational age 31 weeks (+2.54), using carefully standardized anal tical techniques (2). The initial mean PAP was 857 u/l (range 180-2250Yat a mean post-conceptual age of 34.4 wks (r 29-38) . This contrasts with the upper limit in childhood of 825 u/l and adults 330 u/l.
Subsequently 18 infants showed the characteristic increase, peak and decrease pattern in PAP previously described (2). Of this group 4 had radiological proven rickets and a mean peak PAP of 3068 u/l (t443) while the remainder (14) had a mean peak value of 1548 u/l ( d 9 4 ) .
Serial C a and P determinations showed no significant change. The PAP was of bony origin. The data indicate that the upper normal limit of PAP in the PTI is 5 x the corresponding adult value. PAP exceeding 7.5
x the adult reference limit may be compatible with radiological detectable rickets. Anti-rachitic prophylaxis in PTI may have to be reviewed. 
